Severity
Moderate
FDA Drug recall · Reported June 17, 2020
Presence of Particulate Matter: particulate matter identified after reconstitution.
Pfizer Inc. recalled Unasyn (ampicillin sodium/sulbacatam) for injection, 1.5 g* per vial, Rx Only, 10 vials/c… - a moderate-severity action.
Unasyn (ampicillin sodium/sulbacatam) for injection, 1.5 g* per vial, Rx Only, 10 vials/c… was recalled by Pfizer Inc. in June 17, 2020. Reason: Presence of Particulate Matter: particulate matter identified after reconstitution.. Check the official notice for the remedy. Verify recall #D-1306-2020 with the FDA Drug before acting.
The recall
Pfizer Inc. issued this moderate-severity FDA Drug recall-Presence of Particulate Matter: particulate matter identified after reconstitution..
Sourced from official FDA Drug enforcement records. Verify recall #D-1306-2020 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-1306-2020) was formally reported on June 17, 2020, with the manufacturer initiating the action on May 29, 2020. It is classified under Moderate severity (Class II), with a current status of Terminated. Pfizer Inc. is listed as the recalling firm, operating out of New York, NY. Federal records list the affected scope as 94320 units.
The documented reason for this recall is: Presence of Particulate Matter: particulate matter identified after reconstitution. Distribution data in the federal record shows the product reached: Distributed Nationwide in the US. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
94320 units
Related Recalls
6
5 from same agency
Unasyn (ampicillin sodium/sulbacatam) for injection, 1.5 g* per vial, Rx Only, 10 vials/carton, Made in Italy Distributed by Roerig Division of Pfizer Inc. New York, NY 10017 vial NDC 0049-0013-81, carton NDC 0049-0013-83
Presence of Particulate Matter: particulate matter identified after reconstitution.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-1306-2020 |
| Date reported | June 17, 2020 |
| Date initiated | May 29, 2020 |
| Recalling firm | Pfizer Inc. |
| Firm location | New York, NY |
| Affected scope | 94320 units |
| Distribution | Distributed Nationwide in the US |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported June 17, 2020. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.